scholarly journals A Pilot Open-label Study of Aldose Reductase Inhibition with AT-001 (caficrestat) in Patients Hospitalized for COVID-19 Infection: Results from a Registry-based Matched-control Analysis

2021 ◽  
Vol 242 ◽  
pp. 153-154
Author(s):  
Juan Gaztanaga ◽  
Ravichandran Ramasamy ◽  
Ann Marie Schmidt ◽  
Glenn Fishman ◽  
Shoshana Shendelman ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Matched Control ◽  
Control Analysis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Aldose Reductase Inhibition

scholarly journals Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.

1997 ◽  
Vol 41 (12) ◽  
pp. 2793-2796 ◽  
Author(s):  
H J Schaad ◽  
B G Petty ◽  
D M Grasela ◽  
B Christofalo ◽  
R Raymond ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Matched Control ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Age And Gender ◽  
Open Label Study ◽  
Label Study ◽  
Dosing Interval ◽  
Immunodeficiency Virus ◽  
And Gender

This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease.

Azathloprise in refractory sprue. Results from a prospective open-label study

2001 ◽  
Vol 120 (5) ◽  
pp. A392-A392 ◽  
Author(s):  
S NIVELONI ◽  
A CHERNAVSKY ◽  
S PEDREIRA ◽  
R MAZURE ◽  
H VAZQUEZ ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Refractory Sprue

Weighing the Evidence: Can We Believe an Open-Label Study?

2006 ◽  
Vol 16 (4) ◽  
pp. 39-39
Author(s):  
B. L. Wiedermann
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

2017 ◽  
Vol 1 ◽  
pp. s95 ◽  
Author(s):  
Dee Anna Glaser ◽  
Adelaide A Hebert ◽  
Alexander Nast ◽  
William P Werschler ◽  
Stephen Shideler ◽  
...  
Keyword(s):  
Axillary Hyperhidrosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Abstract Not AvailableDisclosure: Study supported by Dermira.

Nefazodone Treatment of Adolescent Depression: An Open-Label Study of Response and Biochemistry

2000 ◽  
Vol 12 (2) ◽  
pp. 97-100 ◽  
Author(s):  
Paul Goodnick ◽  
Cecilia Jorge ◽  
Thomas Hunter ◽  
Adarsh Kumar
Keyword(s):  
Adolescent Depression ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Treatment of Somatization Disorder With Nefazodone: A Prospective, Open-Label Study

2001 ◽  
Vol 13 (3) ◽  
pp. 153-158 ◽  
Author(s):  
Matthew Menza ◽  
Marc Lauritano ◽  
Lesley Allen ◽  
Melissa Warman ◽  
Frank Ostella ◽  
...  
Keyword(s):  
Somatization Disorder ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document